20. April 2012 14:45
The introduction of value-based pricing (VBP) will not solve the issues around the access to new medicines in the UK, a new report says.
Current Stakeholder Perspectives on Value-Based Pricing, a report from charity Myeloma UK, notes 19 recommendations the Government should consider to improve VBP.
Eric Low, Chief Executive of Myeloma UK, said the recommendations “ensure any new system of VBP is the best it can be”.
The report questioned opinion leaders and experts from academia, the NHS, patient groups and the pharmaceutical industry to generate the recommendations.
They focus on price-setting, threshold setting, uncertainty and medicines uptake at a local level. Recommendations include:
- The Government conducting research to establish the relationship between pharmaceutical pricing and the location of research and clinical trial centres
- Cost-effectiveness thresholds under VBP should be set by a new, independent advisory body
- VBP should involve greater coordination between NICE, pharma and other stakeholders to ensure there is appropriate evidence collection about a new medicine prior to its launch
- Determining the value-based price of a new medicine should be a transparent process, but the price agreed could remain confidential to protect the UK as a reference-pricing market.
The Department of Health revealed plans back in December 2010 to replace the existing Pharmaceutical Price Regulation Scheme with a value-based approach from 1 January 2014.